Inventor · disambiguated record
James Brian Parent
Also filed as: PARENT JAMES B · PARENT JAMES BRIAN
11 granted patents·23 pending applications·389 citations·filing 1993–2023
92Inventor score
Top patents by PatentIndex Score
34 records- 0196US9475885B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2015·Granted Oct 25, 2016·15 cites·31 claims
- 0296US8652477B2Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activationSCHWAEBLE HANS-WILHELM·Filed 2010·Granted Feb 18, 2014·61 cites·18 claims
- 0396US7919094B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2006·Granted Apr 5, 2011·86 cites·21 claims
- 0495US8840893B2Methods for treating conditions associated with MASP-2 dependent complement activationSCHWAEBLE HANS-WILHELM·Filed 2011·Granted Sep 23, 2014·36 cites·12 claims
- 0591US9011860B2Compositions for inhibiting MASP-2 dependent complement activationDUDLER THOMAS·Filed 2012·Granted Apr 21, 2015·20 cites·24 claims
- 0691US5348942ATherapeutic uses of bactericidal/permeability increasing protein productsXOMA CORP·Filed 1993·Granted Sep 20, 1994·100 cites·2 claims
- 0786US6333034B1Process for inhibiting complement activation via the alternative pathwayGLIATECH INC·Filed 1998·Granted Dec 25, 2001·71 cites·14 claims
- 0886US2024228665A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 0983US2024092938A1Compositions for inhibiting masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 1081US11884742B2Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2019·Granted Jan 30, 2024·0 cites·14 claims
- 1173US11613589B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2020·Granted Mar 28, 2023·0 cites·13 claims
- 1273US2024076408A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2023·Application pending·0 cites
- 1370US10683367B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2018·Granted Jun 16, 2020·0 cites·33 claims
- 1470US2020190215A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2019·Application pending·0 cites
- 1568US2020040104A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2019·Application pending·0 cites
- 1667US2010074899A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2009·Application pending·0 cites
- 1764US10047165B2Compositions for inhibiting MASP-2 dependent complement activationOMEROS CORP·Filed 2016·Granted Aug 14, 2018·0 cites·9 claims
- 1864US2018291111A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2018·Application pending·0 cites
- 1962US2013266559A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2013·Application pending·0 cites
- 2062US2023391889A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2023·Application pending·0 cites
- 2162US2015064176A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2014·Application pending·0 cites
- 2261US2014205598A1Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2014·Application pending·0 cites
- 2360US2018291112A1Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2018·Application pending·0 cites
- 2459US2016272727A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2016·Application pending·0 cites
- 2559US2021040229A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2020·Application pending·0 cites
- 2657US2017233493A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2016·Application pending·0 cites
- 2756US2017233494A1Methods for Treating Disseminated Intravascular Coagulation by Inhibiting MASP-2 Dependent Complement ActivationUNIV LEICESTER·Filed 2016·Application pending·0 cites
- 2855US2017166660A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2016·Application pending·0 cites
- 2953US2011020337A1Methods for treating conditions associated with masp-2 dependent complement activationOMEROS CORP·Filed 2010·Application pending·0 cites
- 3053US2014056873A1Methods for Treating Conditions Associated with MASP-2 Dependent Complement ActivationOMEROS CORP·Filed 2013·Application pending·0 cites
- 3147US2003198636A1Process for inhibiting complement activation via the alternative pathwayFiled 2003·Application pending·0 cites
- 3244US2002015701A1Process for inhibiting complement activation via the alternative pathwayFiled 2001·Application pending·0 cites
- 3341US2006002937A1Methods for treating conditions associated with MASP-2 dependent complement activationOMEROS CORP·Filed 2005·Application pending·0 cites
- 3441US2006018896A1Methods for treating conditions associated with lectin-dependent complement activationOMEROS CORP·Filed 2005·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →